14/08/2025
10:24 am
Lumos Partners with PRO-spectus for FebriDx Market Access
204KB (3 pages)
13/08/2025
9:20 am
Waiver of ASX Listing Rule 10.1 Granted
236KB (5 pages)
21/07/2025
8:58 am
Q4 FY25 Results Investor Briefing
3303KB (30 pages)
21/07/2025
8:56 am
Quarterly Activities/Appendix 4C Cash Flow Report
512KB (13 pages)
17/07/2025
10:12 am
Proposed issue of securities - LDX
17KB (5 pages)
17/07/2025
10:00 am
Lumos Signs Binding Term Sheet for A$5M Loan Facility
265KB (5 pages)
16/07/2025
10:15 am
Investor Briefing Presentation
1811KB (17 pages)
16/07/2025
10:13 am
Investor Briefing Invitation
217KB (1 pages)
16/07/2025
10:11 am
Lumos Signs Pivotal US FebriDx Agreement
274KB (5 pages)
16/07/2025
10:11 am
Reinstatement to Quotation
116KB (1 pages)
15/07/2025
9:09 am
Suspension from Quotation
252KB (2 pages)
11/07/2025
3:15 pm
Trading Halt
261KB (2 pages)
11/07/2025
2:23 pm
Pause in Trading
113KB (1 pages)
02/07/2025
12:09 pm
Notification of cessation of securities - LDX
15KB (6 pages)
23/06/2025
9:01 am
Lumos Receives Research & Development Tax Rebate
224KB (2 pages)
18/06/2025
9:45 am
Lumos Reaches FebriDx CLIA Waiver Study Enrolment Milestone
253KB (4 pages)
17/06/2025
9:02 am
FebriDx to Support Antimicrobial Stewardship in GP Trial
261KB (3 pages)
02/06/2025
9:08 am
Change of Registered Office and Principal Place of Business
207KB (2 pages)
02/06/2025
9:05 am
Lumos Reaches Recruitment Milestone in FebriDx Study
253KB (3 pages)
27/05/2025
8:59 am
Lumos Secures Sixth US Medicare Reimbursement for FebriDx
308KB (3 pages)
19/05/2025
9:59 am
Lumos Secures Fifth US Medicare Reimbursement for FebriDx
309KB (3 pages)
14/05/2025
9:02 am
Lumos Advances FebriDx Sales with iMedical Purchase Order
221KB (2 pages)
09/05/2025
10:32 am
Notification regarding unquoted securities - LDX
18KB (8 pages)
06/05/2025
8:45 am
Q3 FY25 Investor Briefing
3072KB (25 pages)
29/04/2025
9:00 am
Quarterly Activities/Appendix 4C Cash Flow Report
355KB (14 pages)
23/04/2025
10:46 am
Lumos Secures Further US Medicare Reimbursement for FebriDx
418KB (3 pages)
17/04/2025
10:17 am
Lumos Secures Key US Reimbursement Milestones for FebriDx
398KB (3 pages)
14/04/2025
12:02 pm
Notification of cessation of securities - LDX
16KB (6 pages)
02/04/2025
11:26 am
Investor Presentation
6946KB (35 pages)
24/03/2025
1:51 pm
Investor Information Session Invitation
207KB (2 pages)
03/03/2025
10:58 am
1H FY25 Results Investor Briefing
538KB (9 pages)
03/03/2025
8:43 am
Hologic Development Agreement Expanded Scope of Works
250KB (3 pages)
27/02/2025
8:30 am
Appendix 4D and Half Year Report
672KB (25 pages)
25/02/2025
12:27 pm
1H FY25 Results Investor Briefing Invitation
207KB (2 pages)
05/02/2025
9:08 am
Q2 FY25 Results Investor Briefing Invitation
1166KB (17 pages)
31/01/2025
9:02 am
Quarterly Activities/Appendix 4C Cash Flow Report
428KB (13 pages)
13/01/2025
1:57 pm
Notification of cessation of securities - LDX
14KB (5 pages)
13/01/2025
9:25 am
Lumos Partners with MedPro for Sales of FebriDx in the US
296KB (3 pages)
20/12/2024
1:53 pm
Listing Rule 6.22.2 Adjustment to Option Exercise Prices
222KB (2 pages)
20/12/2024
10:17 am
Application for quotation of securities - LDX
17KB (8 pages)
20/12/2024
10:16 am
Section 708A Cleansing Statement
189KB (2 pages)
19/12/2024
3:53 pm
Commencement of FebriDx CLIA Waiver Study
341KB (3 pages)
13/12/2024
2:34 pm
Notification regarding unquoted securities - LDX opens new window
19KB (8 pages)
10/12/2024
8:54 am
Change of Director's Interest Notice - DW
306KB (3 pages)
06/12/2024
10:05 am
Application for quotation of securities - LDX
17KB (8 pages)
06/12/2024
10:04 am
Section 708A Cleansing Statement
218KB (2 pages)
14/11/2024
8:36 am
2024 AGM Presentation
3411KB (14 pages)
14/11/2024
8:33 am
AGM Chair Address
333KB (3 pages)
29/10/2024
9:26 am
Quarterly Activities/Appendix 4C Cash Flow Report
525KB (13 pages)
16/10/2024
9:45 am
Lumos and BARDA Partnership - Investor Briefing Recording
171KB (2 pages)
14/10/2024
12:28 pm
Cancel - Proposed issue of securities - LDX
16KB (5 pages)
14/10/2024
11:18 am
Proposed issue of securities - LDX
15KB (5 pages)
14/10/2024
10:53 am
Notice of Annual General Meeting and Proxy Form
616KB (30 pages)
11/10/2024
3:14 pm
Change in substantial holding
114KB (2 pages)
11/10/2024
9:21 am
Lumos and BARDA Partnership - Investor Presentation
651KB (9 pages)
10/10/2024
9:11 am
Change of Director's Interest Notice - SL
270KB (3 pages)
10/10/2024
9:06 am
Change of Director's Interest Notice - CR
218KB (2 pages)
10/10/2024
9:03 am
Change of Director's Interest Notice - BLG
219KB (3 pages)
09/10/2024
4:29 pm
Change in substantial holding from RYD
146KB (3 pages)
09/10/2024
3:31 pm
Lumos and BARDA Partnership - Investor Briefing
208KB (2 pages)
09/10/2024
11:45 am
Notification regarding unquoted securities - LDX
19KB (8 pages)
09/10/2024
11:39 am
Application for quotation of securities - LDX
17KB (8 pages)
08/10/2024
8:52 am
Lumos Successfully Completes Retail Entitlement Offer
202KB (3 pages)
03/10/2024
9:33 am
Lumos and BARDA Partner to Support FebriDx CLIA Waiver Study
310.2KB (3 pages)
25/09/2024
12:23 pm
Lumos Awarded National Contract with MediGroup for FebriDx
284.5KB (2 pages)
23/09/2024
4:18 pm
Ceasing to be a substantial holder
65.7KB (1 pages)
23/09/2024
2:35 pm
Change in substantial holding from RYD
177.0KB (3 pages)
23/09/2024
9:43 am
Investor Roadshow Presentation
14.9MB (55 pages)
20/09/2024
10:11 am
Lumos Achieves First Phase 2 Milestone in Hologic Agreement
245.8KB (3 pages)
19/09/2024
4:43 pm
Change in substantial holding
161.3KB (2 pages)
16/09/2024
2:12 pm
Change in substantial holder
193.7KB (2 pages)
16/09/2024
10:54 am
Change in substantial holding
175.1KB (2 pages)
16/09/2024
9:28 am
Lumos Appoints Thermo Fisher Scientific as US Distributor
189.2KB (2 pages)
13/09/2024
3:52 pm
Change in substantial holding from RYD
181.3KB (3 pages)
12/09/2024
10:50 am
Application for quotation of securities - LDX
20.7KB (8 pages)
11/09/2024
9:02 am
Letter to Ineligible Shareholders
134.5KB (3 pages)
11/09/2024
9:02 am
Letter to Eligible Shareholders
19.2MB (98 pages)
11/09/2024
9:01 am
Retail Entitlement Offer Booklet
18.9MB (94 pages)
11/09/2024
9:01 am
Retail Entitlement Offer Opens
237.7KB (2 pages)
06/09/2024
8:54 am
Lumos Successfully Completes Institutional Entitlement Offer
261.3KB (3 pages)
04/09/2024
2:39 pm
Becoming a substantial holder
210.3KB (2 pages)
04/09/2024
12:00 pm
Ceasing to be a substantial holder
125.6KB (2 pages)
04/09/2024
10:53 am
Proposed issue of securities - LDX
18.5KB (5 pages)
04/09/2024
10:52 am
Proposed issue of securities - LDX
24.8KB (7 pages)
04/09/2024
10:38 am
Entitlement Offer Cleansing Notice
232.0KB (3 pages)
04/09/2024
10:38 am
Investor Presentation
18.1MB (53 pages)
04/09/2024
10:38 am
Lumos Announces $10m Equity Raising and Welcomes Tenmile
332.8KB (6 pages)
04/09/2024
9:27 am
Trading Halt
631.9KB (2 pages)
03/09/2024
4:35 pm
Lumos Announces Intention to Undertake Entitlement Offer
334.9KB (3 pages)
27/08/2024
9:39 am
Appendix 4G and Corporate Governance Statement
808.1KB (27 pages)
27/08/2024
9:36 am
FY24 Full Year Results Announcement
287.8KB (5 pages)
27/08/2024
9:29 am
FY24 Annual Report
3.4MB (77 pages)
27/08/2024
9:22 am
FY24 Appendix 4E
201.7KB (2 pages)
26/08/2024
8:39 am
Lumos and BDI Progress New Point of Care Test
329.7KB (3 pages)
05/08/2024
10:21 am
Lumos Receives Research & Development Tax Rebate
286.5KB (2 pages)
01/08/2024
10:13 am
Q4 FY24 Investor Presentation
1.3MB (20 pages)
31/07/2024
8:59 am
Quarterly Activities/Appendix 4C Cash Flow Report
612.1KB (12 pages)
29/07/2024
2:32 pm
Q4 FY24 Results Investor Briefing Invitation
282.4KB (2 pages)
11/07/2024
8:58 am
Notification of cessation of securities - LDX
19.3KB (6 pages)
09/07/2024
8:36 am
Lumos Expands Henry Schein FebriDx Distribution Partnership
273.1KB (3 pages)
04/07/2024
8:34 am
Lumos Expands Distribution for FebriDx in AUS and NZ
425.6KB (3 pages)
19/06/2024
9:52 am
Lumos Receives US$400k Phase 1 Milestone from Hologic
283.0KB (2 pages)
13/06/2024
9:40 am
Change of Director's Interest Notice - CR
311.5KB (2 pages)
13/06/2024
9:39 am
Change of Director's Interest Notice - SL
317.7KB (2 pages)
04/06/2024
9:12 am
Lumos Receives Second US$5 million Hologic IP Payment
245.3KB (3 pages)
28/05/2024
11:37 am
March 2024 Appendix 4C - Correction
564.5KB (7 pages)
06/05/2024
8:41 am
Lumos Achieves Key Phase 1 Milestone in Hologic Agreement
309.0KB (3 pages)
02/05/2024
2:23 pm
Lumos quarterly update video interview with CEO, Doug Ward
221.5KB (2 pages)
01/05/2024
12:09 pm
Notification regarding unquoted securities - LDX
21.3KB (8 pages)
23/04/2024
9:10 am
Quarterly Activities/Appendix 4C Cash Flow Report
560.2KB (11 pages)
08/04/2024
9:29 am
Lumos announces positive FebriDx paediatric study results
374.9KB (4 pages)
02/04/2024
5:13 pm
Change in substantial holding
154.1KB (2 pages)
02/04/2024
3:31 pm
Application for quotation of securities - LDX
21.1KB (8 pages)
02/04/2024
3:29 pm
Section 708A Cleansing Statement
191.8KB (2 pages)
29/02/2024
5:50 pm
Change in substantial holding
229.5KB (2 pages)
28/02/2024
8:54 am
Half Year Results Investor Presentation
3.8MB (32 pages)
28/02/2024
8:51 am
Appendix 4D and Half Year Report
1.4MB (28 pages)
23/02/2024
11:58 am
1H FY24 Results Investor Briefing Invitation
252.9KB (2 pages)
14/02/2024
4:38 pm
Change in substantial holding
177.2KB (2 pages)
12/02/2024
9:12 am
Lumos Appoints Henry Schein as US Distributor for FebriDx
284.8KB (2 pages)
05/02/2024
9:55 am
Lumos Investor Roadshow Presentation
1.5MB (25 pages)
31/01/2024
9:24 am
Investor Information Sessions
286.7KB (2 pages)
31/01/2024
9:21 am
Quarterly Activities/Appendix 4C Cash Flow Report
599.4KB (12 pages)
19/01/2024
2:46 pm
Proposed issue of securities - LDX
30.2KB (6 pages)
19/01/2024
2:42 pm
Notification regarding unquoted securities - LDX
34.1KB (9 pages)
17/01/2024
12:00 pm
Change in substantial holding
166.3KB (2 pages)
16/01/2024
10:35 am
New Hologic Agreements Investor Briefing Presentation
524.2KB (8 pages)
16/01/2024
10:34 am
Additional Information Regarding Agreements with Hologic
229.5KB (3 pages)
15/01/2024
2:31 pm
Notification of cessation of securities - LDX
27.7KB (6 pages)
15/01/2024
2:20 pm
Investor Briefing on new Hologic Agreements
258.3KB (2 pages)
11/01/2024
9:43 am
Lumos Signs Major Development and IP Agreements with Hologic
236.3KB (3 pages)
07/12/2023
2:05 pm
Change in substantial holding
240.8KB (2 pages)
06/12/2023
8:48 am
Commercial Operations Update Webinar Presentation
19.9MB (12 pages)
04/12/2023
1:35 pm
Commercial Update Webinar US Product Launch Activities
211.9KB (2 pages)
04/12/2023
8:35 am
Lumos Diagnostics FY2023 Full Year Results Webinar
211.0KB (2 pages)
14/11/2023
2:13 pm
Becoming a substantial holder from RYD
171.6KB (2 pages)
03/11/2023
3:55 pm
Change in substantial holding
216.9KB (2 pages)
03/11/2023
11:35 am
Section 708A Cleansing Statement
293.6KB (2 pages)